Skip to content New The AI buying guide for BD&L executives — now available on demand Watch
Where to build

VibeOne Indication Prioritization

Find the therapeutic areas worth building a program in. Evaluate thousands of indications against your strategy and get results in minutes vs. months.
VibeOne · Indication Prioritization Live
What’s missing today

Challenges in the current process

It's slow

Assessing indications by hand takes months. The answer can be out of date before a decision is made.

It's fragmented

There are 20,000+ indications to explore. The data on each one is spread across papers, trials and databases.

It doesn't scale

Each round depends on consultants and subjective criteria, and the results are static once delivered.

The VibeOne difference

Faster answers, in one place, on your terms

Answers in minutes, not months

One pharma client ran each indication analysis round in 10 days, 18x faster than its prior six-month process.

All the data in one place

Every indication in one ranked view. Each rank links back to its data, trials and papers.

Scale without added headcount

Rank indications against your team's own objective criteria, in place of a consulting-led process.

Configurable criteria

From modality fit to competition, patient population, clinical endpoints and custom dimensions. Rigorously score every indication.

Inside the analysis

Every indication in scope, sorted into tiers

Weight the criteria your way and the whole portfolio re-ranks against it.

VibeOne Indication Prioritization analysis, animated
Case study · Bial

20,000+ indications narrowed to a five-program pipeline

Portuguese pharma group, founded 1924. CNS and neuroscience focus.

The problem

Bial is building a rare disease business unit from scratch. They needed to find new therapeutic areas to develop novel drug programs.

What VibeOne did

VibeOne analyzed all 20,000+ known diseases and rigorously assessed each one against Bial's custom criteria, including biology, unmet need, clinical endpoint validation, competitive landscape and peak sales potential. It then helped the team deep dive on each priority.

The result

Bial has initiated multiple new therapeutic programs from the analysis, including in disease areas introduced to them first by VibeOne.

20,000+
Rare disease indications assessed
10 days
per analysis round, vs. 6 months with their prior process
2
New drug programs have started, and the collaboration is still expanding.
“This was a game changer -- Now we are building drug programs in disease areas that we had never heard of until we used VibeOne.”
Smitha Jagdish, PhD, VP, Rare Disease and New Modalities, Bial

Find your next asset with confidence.

See the evidence, the gaps, and how it compares.